Antibody Validation Market Size

  • Report ID: 5010
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Antibody Validation Market Size

Antibody Validation Market size was valued at USD 341.1 Billion in 2023 and is likely to reach USD 1.81 Trillion by the end of 2036, expanding at around 13.7% CAGR during the forecast period i.e., between 2024-2036. In the year 2024, the industry size of antibody validation is assessed at USD 383.16 Billion. This growth of the market is anticipated to be influenced on account of growing cases of COVID-19. A large number of people were found to have symptoms of COVID-19 but were not been tested. Hence, due to this, the COVID-19 antibody validation demand was boosted. For instance, to treat COVID-19, an estimated 70 monoclonal antibodies are currently being developed or are through clinical studies.

Moreover, similar to COVID-19 there are numerous other diseases that are set to spread among people. These diseases include Ebola, Marburg virus disease, Lassa fever, MERS-CoV, SARS, and more. However, most of these diseases have no vaccine and research is yet to be conducted. These diseases are referred to as "Disease X," a pandemic-causing sickness that would never have been encountered by mankind before. COVID-19 has been identified as Disease X, prompting scientists to rush to discover therapies and vaccinations to combat it. Hence, in order to avoid the covid19 situation in the coming years, the demand for antibody validation is growing.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 5010
  • Published Date: Aug 01, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of antibody validation is assessed at USD 383.16 Billion.

The antibody validation market size was valued at USD 341.1 Billion in 2023 and is likely to reach USD 1.81 Trillion by the end of 2036, expanding at around 13.7% CAGR during the forecast period i.e., between 2024-2036. The major factors driving the growth of the market are the growing prevalence of autoimmune disease, the rise in the need for early detection of cancer, and the advancement of strategies.

North America industry is set to garner the highest revenue by 2036, backed by growing prevalence of HIV, along with rising investment in research and development.

General Electric, Merck KGaA, Thermo Fisher Scientific Inc., F. Hoffmann La-Roche Ltd, Rockland Immunochemicals Inc., Johnson & Johnson private Limited, Agilent Technologies Inc., Eli Lily and Company, Becton, Dickinson and Company, Danaher
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample